The FDA is changing its tune on Jardiance, a Boehringer Ingelheim diabetes med it hasn't been so keen on in the past. After rejecting the drug in the face of a manufacturing issue, the agency Friday gave it approval to treat Type 2 diabetes. A member of the SGLT2 class, it will compete with Johnson & Johnson's ($JNJ) Invokana and AstraZeneca's ($AZN) Farxiga come launch time. Release | More